These ASX shares could rise 20% to 45%

Analysts are tipping these stocks to smash the market in 2025.

| More on:
A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are you on the lookout for some big returns? If you are, then it could pay to listen to what brokers are saying about the ASX shares in this article.

That's because they have been named as buys and tipped to rise more than 20% from current levels. Here's what they are saying:

Boss Energy Ltd (ASX: BOE)

Bell Potter sees plenty of upside in this uranium miner. The broker currently has a buy rating and $4.70 price target on its shares. This implies potential upside of 46% for investors over the next 12 months.

The broker believes that the ASX share is undervalued at current levels and could be destined to have a re-rating if its second quarter result is in line with expectations. It said:

We continue to view BOE as being attractively priced (FY25 Forward EV/EBITDA 6.6x) vs peers, which could warrant a re-rate post the 2QFY25 result, should production and costs track in-line with our expectations. We maintain our conviction in Uranium and Nuclear over the coming 12m and our Buy recommendation and $4.70/sh Target price for BOE.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Goldman Sachs thinks that medical device company Fisher & Paykel Healthcare could be an ASX share to buy. It put a buy rating and $42.70 price target on its shares this month. This implies potential upside of 23% for investors over the next 12 months.

The broker highlights that Fisher & Paykel Healthcare is well-placed for growth through to FY 2030 thanks to its hospital segment and large addressable market. It said:

Our Buy thesis is underpinned by (1) Acceleration of revenue in the hospital segment (+15.1% FY24-FY30E CAGR) assisted by an expansion to FPH's Total Addressable Market (TAM), (2) Favorable point in the product cycle with several new launches across CY22-24 driving Gross Margin (GM%) expansion and mitigating downside risks from potential US policy changes, and (3) Opportunity in the Nasal High Flow Therapy (NHFT) home segment where certain regions have commenced reimbursements.

HMC Capital Ltd (ASX: HMC)

The team at Bell Potter is also bullish on this diversified alternative asset manager and sees it as an ASX share to buy. The broker recently put a buy rating and $13.50 price target on its shares. This suggests that they could rise 46% between now and this time next year.

Its analysts believe that recent share price weakness has created an attractive entry point for investors. It said:

It has been remarkable half year period for HMC and we upgrade to Buy (was Hold). We think the share price pull-back provides an attractive entry point as the platform is reaching a scale and breadth sweet spot juncture which could see fee-earning capability increase further yet, and screens inexpensively vs. key global alternative AM and real estate fund manager peers.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and HMC Capital. The Motley Fool Australia has recommended HMC Capital. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Successful group of people applauding in a business meeting and looking very happy.
Broker Notes

Bell Potter names the best ASX 200 shares to buy in February

The broker believes these shares could generate big returns for investors.

Read more »

Investor sitting in front of multiple screens watching share prices
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Broker Notes

5 ASX 200 stocks that could negatively surprise during earnings season

Warning bells are ringing for analysts at Goldman Sachs this earnings season.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

Guess which ASX 200 stock Bell Potter just upgraded

Let's see why the broker is feeling bullish about this stock.

Read more »

A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
Broker Notes

2 Australian stocks to buy with $5,000 after the market selloff

Analysts are tipping these shares to deliver big returns for investors.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These top ASX shares could rise 30% to 60%

Let's see why analysts are so bullish on these names this week.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »